Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab Combined With SOX in Adjuvant Gastric Cancer
NCT05184946Phase 2Unknown
- Sponsor
- Second Affiliated Hospital of Shandong First Medical University
- Start
- Oct 2021
- Primary completion
- Oct 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Second Affiliated Hospital of Shandong First Medical University. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05184946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05184946.